---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-191944"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T02:18:55.046018+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Olema Pharmaceuticals appoints Dr. Prakash Raman to Board of Directors

## Summary
- Dr. Raman appointed as Class II director effective April 28, 2026; term expires at 2028 annual meeting.
- He brings over 20 years of biopharma experience; currently CEO of InduPro Therapeutics.
- Received initial equity grants: option for 24,150 shares vesting monthly over 3 years, plus 2,911 shares vesting June 11, 2026.
- Company highlights lead program palazestrant in two Phase 3 trials with OPERA-01 data expected fall 2026.
- Board determined Dr. Raman is independent under Nasdaq rules.

## SEC filing metadata
- accession: 0001193125-26-191944
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000119312526191944/0001193125-26-191944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000119312526191944/olma-20260427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-191944
- JSON: https://secwatch.observer/filing/0001193125-26-191944.json
- Plain text: https://secwatch.observer/filing/0001193125-26-191944.txt

## Key facts
- Executive change
  Prakash Raman was appointed as Class II director at Olema Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Class II director
  source text: the Board appointed Dr. Prakash Raman to the Board as a Class II director, effective April 28, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750284/000119312526191944/0001193125-26-191944-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.